Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NUHscHh{TnWwY4Tpc44hSXO|YYm= MnfJNkDPxE1? Mm\1NUBp MYPpcohq[mm2czD0bIUhVC2GT2DBJEgzOMLizszNLU1qdmS3Y3XkJJRz[W6|aXXueEBGWktzL{KgdIhwe3Cqb4L5cIF1cW:wwrC= NUHF[XdsOjZ|NkOxPVE>
C2C12 MlfxSpVv[3Srb36gRZN{[Xl? M3zq[VHDqM7:Zz;tcC=> NV\s[XVtOcLiaB?= MWfhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz NIXYT5AzPjJ7MUK3PS=>
MEFs WT MkDsSpVv[3Srb36gRZN{[Xl? MYq1xsDPxE1? M1\5NVIxKG2rbh?= NEWwVGFk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU M2TSUVI3OTl4MEKz
MEFs VAMP7 KO MnfOSpVv[3Srb36gRZN{[Xl? NYLrepZKPcLizszN MUSyNEBucW5? MUHjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT NFr5cm0zPjF7NkCyNy=>
SMCs NHXVUpdHfW6ldHnvckBCe3OjeR?= NV3BfJh2OTEEoNM1[{9udA>? NX7xb49KOC1zMjDo MnzDSG1UVw>? M2rJXpNpd3e|IHGgeJJmdmRidH;3ZZJleyCjIHjp[4hmeiClb37j[Y51emG2aX;uJI9nKHSqZTDFVk9UWiCwZYT3c5JsKGmwIITo[UBx\XKrboXjcIVieiCjcnXhxsA> NUXxb4xJOjZzN{KwPFA>
SMCs NWC0UIdYTnWwY4Tpc44hSXO|YYm= NV:0dnhWOTEEoNM1[{9udA>? MYmwMVEzKGh? Ml[0SG1UVw>? MoDNZ4F2e2W|IHGgeJJidnOrZX70JGNiOiwEoILlcIVie2ViZoLvcUB1cGViRWKvV3LDqA>? NHvKcFkzPjF5MkC4NC=>
HEMC-1 MXvGeY5kfGmxbjDBd5NigQ>? MUewMlHDqML3Zz;tcC=> MlzJNlTDqGh? MXvjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= NX:xNFgyOjV7N{K3OVk>
HUVEC NHO0fohHfW6ldHnvckBCe3OjeR?= M{jiV|ExyqEQvF2= NGH3flUyyqCq Mn\WSG1UVw>? NGDEeYRi[m:uaYPo[ZMhcHmyb4jpZU1qdmS3Y3XkJJJmdGWjc3Wgc4YhSVSSIH\yc40h[XCrY3HsJIFv\CCkYYPvcIF1\XKjbDDzeZJn[WOncx?= NGrxU5AzPTl3Nkm4PC=>
HUVEC M{\yeGZ2dmO2aX;uJGF{e2G7 NIHvTokyOMLizszN NWLVZVFPOcLiaB?= MoLXSG1UVw>? MmDqbY5kemWjc3XzxsB1cGViboXtZoVzKGGwZDDpcpRmdnOrdImgc4Yh\my3b4Lld4NmdnRiYYLlZZMh\XOyZXPpZYxtgSCrbjDw[ZJqdnWlbHXhdkB{eGGlZR?= NW\ScItiOjV7NU[5PFg>
Caco-2 MVfGeY5kfGmxbjDBd5NigQ>? NWLJR5Z1Oi53IN88US=> MmPyN|AhdWmw NFjQZZpifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? NUD1[mU3OjV7NUS5N|E>
NRK NH\SPJlHfW6ldHnvckBCe3OjeR?= Mm\1NlAx6oDHbnevcYw> MoW3OQKBjWh? MnrUSG1UVw>? NXXueHMyemW|Y4Xld{BucXSxdHnjJJBzd2e{ZYPzbY9v MV2yOVk1QDV6Nh?=
HeLa MlfmSpVv[3Srb36gRZN{[Xl? M2\xO|IxOOLChX7nM41t NWLvdmFwOyCq Mkm1SG1UVw>? NXzaOoJFcW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> MkXCNlU6PDh3OE[=
COS MlrSSpVv[3Srb36gRZN{[Xl? M{XGUVEh|rypL33s M3uwVVMhcA>? M1rPV4NwdXCuZYTlcJkh\Gm|cHXyd4V{KHSqZTDBVE0yKHOrZ37hcOKh NETBNGUzPTlzNUmwNC=>
DF1  NYHyZ5JGTnWwY4Tpc44hSXO|YYm= MVOxxsDPxE4EoB?= NWnSNlBmPDhiaB?= NX62c|FSTE2VTx?= M4C5fIRqe3CncoPld:KhfGinIHX4c4dmdm:3czDDV2didE6DY2SyJJBzd3SnaX6= Ml3KNlU5ODdyNUS=
nHDFs  NGLKdWxHfW6ldHnvckBCe3OjeR?= MoXaNeKh|ryPwrC= M3q0blLDqGh? NWjpfXdieHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz M4m3WVI2Pzd{NkG2
FRT  MnXISpVv[3Srb36gRZN{[Xl? NH[zWW02KM7:Zz;tcC=> MlHMNuKhcA>? M1LTRoJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 MlTkNlU4PjdzMUW=
FRT  MV7GeY5kfGmxbjDBd5NigQ>? NEj2Slg2KM7:Zz;tcC=> M{WwZlLDqGh? NVTwXGxVeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJINt\WG4ZXSg{tEhe3WkdX7peJMhf2inbjDbUoEsZWoEoIfhd{Bz\WS3Y3Xk NELXOWozPTd4N{GxOS=>
HepG2  NUHCV21pTnWwY4Tpc44hSXO|YYm= MXSx5qCKyrWPwrC= NX:zflhkOjRiaB?= MmjuSG1UVw>? Mmno[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? MX:yOVYyPjV7Nx?=
SMCs M3PR[mZ2dmO2aX;uJGF{e2G7 M2DpZlHPxGdxbVy= MlPSN{Bp Mn7HZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= M3XtcFI2PTh7NEK1
OB-6 NVrPc5BJSXCxcITvd4l{KEG|c3H5 NILtToEzNjgEoN88US=> NH\zPGE1QCCq MnnobY5lfWOnczDhdI9xfG:|aYO= M{jq[|I2PTN{NEiw
iPSC-CMs  MXHGeY5kfGmxbjDBd5NigQ>? NYOwWHV2PTByIH7nM41t MojNOFghcA>? MV;pcoNz\WG|ZYOgeIhmKGmwdHXud4l1gSCxZjD0bIUhcGmpaHXyJI1w[mmuaYT5JGxCVVC|IHH0JJRp\SClb4P0JI9nKHSqZTDsc5dmeiCvb3LpcIl1gSC|cHXjbYV{ NHHuO|EzPTR6OE[2Oi=>
SP-Nluc M{m0PGZ2dmO2aX;uJGF{e2G7 NYnKT4k1PSCvZz;tUC=> NVTxW45lPiCq NXn5S5JxTE2VT9Mg MXHjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl NEfjeFYzPTN7Mkm5PC=>
PEXEL-Nluc MoD6SpVv[3Srb36gRZN{[Xl? MojiOUBu\y:vTB?= NVSySolwPiCq MYfEUXNQyqB? M2D3eINifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> Mk\nNlU{QTJ7OUi=
H1299 M13HW2Z2dmO2aX;uJGF{e2G7 M{Xk[|ExKM7:Zz;tcC=> M1XFNVI1KGh? M4HCdIlv\HWlZYOgZZV1d3CqYXf5xsA> NEDEc3YzPTN6OEm3NC=>
MDA-MB-231 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV:w5qCUPTBizsznM41N MlLtOFghcA>? M4n3PGVEPTEEoE2gNE4xOTZiwsXnM41N MYWyOVM2PjV4Nx?=
MDA-MB-231 M{jTOGFxd3C2b4Ppd{BCe3OjeR?= NFHCWlcxNjFizsznM41N MoPPOEBp MWHpcoR2[2W|IHHwc5B1d3Orcx?= M1Xj[FI2OzV4NU[3
MDA-MB-231 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TJXlAvODFxMD6wOUDPxGdxbVy= M3:1flI1KGh? MX3pcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIIP1Zk1IOSClZXzsJIRm[nKrcx?= NHi4U5kzPTN3NkW2Oy=>
MDA-MB-231 MX\BdI9xfG:|aYOgRZN{[Xl? NV35WZZROC5yNfMAl|Eh|rypL33M MkfiNlQhcA>? MVLpcoR2[2W|IGDBVnAhMHCxbImgRWRRNXKrYn;z[UBxd2y7bXXyZZNmNTFrIHPs[YF3[Wen NV\keWtjOjV|NU[1Olc>
MDA-MB-231 MVjGeY5kfGmxbjDBd5NigQ>? M3fYelDjiJN3MDFOwIcwdUx? MX2yOEBp M4PGNolvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz MlP0NlU{PTZ3Nke=
A172 Mnn5SpVv[3Srb36gRZN{[Xl? NEDkOG4yOMLizsznM41t MojROOKhcA>? NYKzV5hnTE2VT9Mg M1nxUpJme3WudIOgbY4hfGinIILleJJw\3KjZHWgeJJidnOyb4L0JI9nKG[udX;y[ZNk\W62IHfyZY52dGW| MmPRNlUzOzl3MEe=
KMS-6 M2mwXGZ2dmO2aX;uJGF{e2G7 MmL5NeKh|ryPwrC= MYiyOEBp M37HXYV5cGmkaYTzJIhidGZidHjlJJNm[3KndHnvckBw\iCpYXzhcolvNUyLIHHzJIRq\CC2aHWgZ49vfHKxbB?= NFj1XIgzPTJ{OUGyOi=>
MEC NH21[5BHfW6ldHnvckBCe3OjeR?= NYPjOmpLOSEQvF2= NEf5fIkyNjViaB?= MoHkZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz NXS2T2ZSOjV{Mki4NVU>
HEK293/hERG NFflTJhHfW6ldHnvckBCe3OjeR?= NGnVNG0yOMLizszN NHf1TYYyyqCq Mn6zdoV{fWy2czDpckBiKHSrbXWt[IVx\W6mZX70JJJm\HWldHnvckBu[XS3cnWgbGVTTyCycn;0[YlvyqB? NGHSSJozPTJzOES2PS=>
RBE4 NV3zVYVsSXCxcITvd4l{KEG|c3H5 MlruNuKh|ryP MWez5qCUOjUEoHi= M2rnVolv\HWlZYOgZZBweHSxc3nzJJRqdWViZHXw[Y5l\W62bIm= NYHk[Ww{OjVzMkiwNlU>
RBE4 MYrGeY5kfGmxbjDBd5NigQ>? NF;nWIMzyqEQvF2= MUCz5qCUOjUEoHi= MYLpcoNz\WG|ZYOgeIhmKFiEUEGgdJJwfGWrbjDs[ZZmdHNiYX\0[ZIhOyCjbnSgOuKhcCCxZjD0doVifG2nboS= NF;1OIMzPTF{OECyOS=>
RBE4 Mn3wSpVv[3Srb36gRZN{[Xl? M3q3NVLDqM7:TR?= NH7lSpo{6oDVMkVCpIg> NVX0eYwycW6lcnXhd4V{KGGldHn2[UBk[XOyYYPlMVEzKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? M4Dz[lI2OTJ6MEK1
RBE4 NGjBO3ZHfW6ldHnvckBCe3OjeR?= NWrGe4tyOsLizszN MYOz5qCUOjUEoHi= MX;pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUT2OgeIlu\S2mZYDlcoRmdnSueR?= NXPwRoc5OjVzMkiwNlU>
RBE4 NVXVPHlQTnWwY4Tpc44hSXO|YYm= NIS1OYszyqEQvF2= M160WFPjiJN{NNMgbC=> NI\3fXBqdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm= Ml25NlUyOjhyMkW=
RBE4 NYHYV2JZTnWwY4Tpc44hSXO|YYm= NEXqeFYzyqEQvF2= NWC5OnlsO+LCk{K0xsBp NVL6VVBHcW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NFrJfogzPTF{OECyOS=>
Huh-7  NF3jfFZHfW6ldHnvckBCe3OjeR?= NGj2[2Ey|rypL33M M3PGO|PjiJN{NNMgbC=> NXf6bpRncW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NW[3dnZIOjVyMk[xO|Q>
HepG2  M3fLVGZ2dmO2aX;uJGF{e2G7 Mn;KNe69\y:vTB?= Mn3YN-KBmzJ2wrDo MVfpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFXpTmUzPTB{NkG3OC=>
H838-LKB1 NX7OPXNwTnWwY4Tpc44hSXO|YYm= MnKxN|DDqG6pL33s MoL1NVIwOThiaB?= NV3kc21ocW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NVLjN4NtOjVyMUGwPFI>
H838-KDLKB1  MlXuSpVv[3Srb36gRZN{[Xl? M4nXOFMxyqCwZz;tcC=> MUmxNk8yQCCq MV7pcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg MVSyOVAyOTB6Mh?=
H838-KDLKB1  NXHZNXFiTnWwY4Tpc44hSXO|YYm= NGXpTIc{OMLibnevcYw> M{DIblEzNzF6IHi= NVX4R5lNcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1\WRiZVnGNu6yKCiyaH;zdIhwNWWLRkNOtUk> MYKyOVAyOTB6Mh?=
3T3-L1 M2D0UmZ2dmO2aX;uJGF{e2G7 NXjzWI1IPSEQvHevcYw> MXKzNEBucW5? M3PhZ41qdWmlczD0bIUh\W[oZXP0d{Bw\iCrboP1cIlvKGGwZDDjZZV{\XNicn;ieZN1KHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgLHNmeiB2N{OpJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiQWOxOlAhMFSqcjC2OFIh[W6mIGPldkA2QDhr MmnZNlQ5PDN6Mke=
3T3-L1 MWPGeY5kfGmxbjDBd5NigQ>? M4LTWlUh|rypL33s M1PoZVMxKG2rbh?= M1HROJJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? MYCyOFg1Ozh{Nx?=
3T3-L1 M{OxUmZ2dmO2aX;uJGF{e2G7 M37I[FUh|rypL33s MXmzNEBucW5? NYH5S3M{[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= MVuyOFg1Ozh{Nx?=
3T3-L1 NWjZcXN7TnWwY4Tpc44hSXO|YYm= NWHEVoNqPSEQvHevcYw> NUX0V4ZqOcLiaB?= M3HCT4NifXOnczDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPCCkdYSgco91KGmwY4LlZZNmKGmwIHfseYNwe2VidYD0ZYtm Mn3YNlQ5PDN6Mke=
3T3-L1 NHXUNpNHfW6ldHnvckBCe3OjeR?= NWrncWN{PSEQvHevcYw> NIn3U3gyyqCq NXzOe5o5[2G3c3XzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3J? M17sZlI1QDR|OEK3
HeLa  MoPlSpVv[3Srb36gRZN{[Xl? M1fXflUh|rypL33s NEi1Nmw{KGh? M1u0c4NifXOnczDueYNt\WG{IHX4Z4x2e2mxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3JiYX7kJIRm[3KnYYPld{B1emGwc3PybZB1cW:wIH;mJGZwgE9zLYLl[5Vt[XSnZDDn[Y5mew>? NV;lb2FDOjR6NEO4Nlc>
HEK293 NGDJTHlHfW6ldHnvckBCe3OjeR?= MWS1xsDPxGdxbXy= M3juZ|EzyqCq MUXhZo9tcXOqZYOgR21CNWmwZIXj[YQhS1KHTFSyJJNm[3KndHnvci=> NF;NTWgzPDZ6N{SzNS=>
COS-1 M4Pq[mZ2dmO2aX;uJGF{e2G7 NH\YeWM2KML3Zz;tcC=> M3naTFI1KGkEoB?= M2rpd5Jme3S{aXP0d{Btd2OjbHn6ZZRqd25ib3[gUmIhcW5idHjlJJBmemmwdXPs[YFzKHKnZ3nvcuKh NHvNWXAzPDZ5MUe1NS=>
PRP MlTESpVv[3Srb36gRZN{[Xl? NXPRXpRmOTBizszN MV\hZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? MYOyOFY3QDd3MB?=
RAW264.7 NFnBXoZCeG:ydH;zbZMhSXO|YYm= MmTSOEDPxE1? NVGxUY92PDhiaB?= NIfaSHhifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= M2nQWFI1PjN7MEOy
MDMs NFXRTmJCeG:ydH;zbZMhSXO|YYm= MnP5NVDjiIoQvHevcYw> MX2xNk8yPSCq M3GxOolv\HWlZYOgZZBweHSxc3nz Mmj1NlQ2PTZ4OUW=
PMHs  MUjGeY5kfGmxbjDBd5NigQ>? MVexNQKBmzJy4pEJ{txoN22u MXiyOQKBkWh? NFmyPG1FVVOR MmX3bY5lfWOnZDDFVkB{fHKnc4O= M1jl[VI1PDB5MkSy
PMHs  MXLBdI9xfG:|aYOgRZN{[Xl? MV[xNQKBmzJy4pEJ{txoN22u NHnrRXIzPOLCiXi= MYDEUXNQ MYfpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> MmfONlQ1ODd{NEK=
HEK293/tau MV3GeY5kfGmxbjDBd5NigQ>? MnnUOUDPxE1? MnT2NU8zNzRiaB?= NULqdoJKcW6mdXPld{BId2ypaTDmdoFodWWwdHH0bY9vyqB? MWSyOFM3QDB6OR?=
HEK293/tau MoD3SpVv[3Srb36gRZN{[Xl? M1X5SlUh|ryP NXvQO284OyCq MYrpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? M1fqelI1OzZ6MEi5
ADF MXXGeY5kfGmxbjDBd5NigQ>? MV2xNEDPxE1? NXnBR|NsOTZiaB?= Mn[1bY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> NVj1d4FiOjR{MkiyN|I>
U373  M4rzeWZ2dmO2aX;uJGF{e2G7 NXrFRVZFOTBizszN MmL6NVYhcA>? NHTDPZVqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? M3LufFI1OjJ6MkOy
RKO-HIPK2i MVzGeY5kfGmxbjDBd5NigQ>? NEDhNYMyOCEQvF2= M3yybVE3KGh? MVPpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> M2XrcVI1OjJ6MkOy
ADF  M4PqV2Z2dmO2aX;uJGF{e2G7 MkjBNVAh|ryPwrC= NXzjZXlrPiCq NHXTeXRqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u M1vJPFI1OjJ6MkOy
Huh7 M1rK[GZ2dmO2aX;uJGF{e2G7 NW\NT4VjPSEQvHevcYw> MonsOEBp M2\ucYFjd2yrc3jld{B1cGVic3XjdoV1cW:wIH;mJEBqdnS{YXPlcIx2dGG{IFHwc2I> NYHvdog1OjRzMECxOFA>
Huh7 MX3GeY5kfGmxbjDBd5NigQ>? Mor2OUDPxGdxbXy= NU\IT4VqOSCq Ml\mZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> M1nseVI1OTByMUSw
Huh7 M4nLPWZ2dmO2aX;uJGF{e2G7 MkfVOgKBmzFywrDu[{9udA>? Mn[2NVIhcA>? NIDjSVZqdmO{ZXHz[ZMhSXCxQj3jdoV{[2WwdIOge4l1cG:3dDDpcohq[mm2aX7nJJNm[3KndHnvci=> M1XYWVI1OTByMUSw
BAECs M{CxXWZ2dmO2aX;uJGF{e2G7 MnLkOUDPxGdxbXy= NIDTVHYxNTRiaB?= MXzpcoR2[2W|IITo[UBz[XCrZDDk[ZBpd3OyaH;yfYxifGmxbjDv[kBmVk:VIHH0JHNmejFzN{m= MVWyOFA5PTJ{NR?=
Macrophages NYTWXpZzTnWwY4Tpc44hSXO|YYm= NXHBOot7PzFiwsXN MWO2JIg> MXPpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi M{jNd|I1ODN7N{Sw
Colo 205 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLrNE02KM7:Zz;tUC=> NXjSV2hxPDhiaB?= MlnjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= M{jVcVI{QTd|OUm2
Colo 205 NVnRcGpPTnWwY4Tpc44hSXO|YYm= NGHCS5AxNjBzMj2wMlAzPSEQvHevcWw> M4DySFE1KGR? NXO1NZRvemWmdXPld{B1cGViY3zvco9o\W6rY3n0fUBw\iCFb3zvJFIxPSCFU1Pz MoC1NlM6PzN7OU[=
Colo 205 MWnBdI9xfG:|aYOgRZN{[Xl? M1LFZlAvOSEQvHevcWw> NI\FS4YxNTJ2IHi= NFnTRZZqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCFb3zvJFIxPSClZXzsd{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW| MkjXNlM6PzN7OU[=
Colo 205 MWDGeY5kfGmxbjDBd5NigQ>? MYqwMlAyPSEQvHevcWw> MWWyOEBp M1zVZolv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? MWWyN|k4Ozl7Nh?=
Colo 205 MlXWSpVv[3Srb36gRZN{[Xl? NIHPOXExNjBzNTFOwIcwdUx? M33nSlI1KGh? NI[0UWtqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1Rew>? M4HjblI{QTd|OUm2
IBRS2 M3PuRWZ2dmO2aX;uJGF{e2G7 NGjWNJI2KM7:Zz;tcC=> MoLONE42KGh? MnzaSG1UVw>? Mojq[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh MmDqNlM6PjN3M{S=
IBRS2 MmXySpVv[3Srb36gRZN{[Xl? NVrKW|NIPSEQvHevcYw> M1HnUlAvPSCq M2HjW2ROW09? NV7Qd2hF\W6qYX7j[ZMhTk2GVjDpcoZm[3Srb36= NWTzU4ZxOjN7NkO1N|Q>
HeLa MUjGeY5kfGmxbjDBd5NigQ>? MnnGNkDPxE1? M3TwNFIhcMLi NF7HcmdifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> MVyyN|k2ODh7Mh?=
HFS  MlfsSpVv[3Srb36gRZN{[Xl? NHPpXHQxNTFizsznM41t NEfzRpozPCCq MV\HUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s NYHNTlNROjN6OUS2N|M>
HFS  NVLET5FRTnWwY4Tpc44hSXO|YYm= MXuwMlAyKML3Zz;tcC=> MoHQNlQhcA>? MkTVbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? MYSyN|g6PDZ|Mx?=
OVCAR-3 M3XnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLa[pZJOeLCk{G1xsDPxE4EoB?= Mn7ONlTDqGh? M4P4UYlv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MUCyN|gzPjl4NB?=
OVCAR-3 M1TURmZ2dmO2aX;uJGF{e2G7 MmPjNgKBmzF3wrFOwG3DqA>? MV[yOOKhcA>? NULvWmhtcW6mdXPld{BvfWOuZXHyJIRidWGpZR?= MVyyN|gzPjl4NB?=
OVCAR-3 MWjBdI9xfG:|aYOgRZN{[Xl? M2rzT|EuOTEEoN88US=> NWfVPGdrPCCq NWXYd|hmcW6mdXPld{B1cGViYXP0bZZifGmxbjDv[kBieG:ydH;zbZMuemWuYYTl[EBxem:2ZXnudy=> NHu5OY8zOzh{Nkm2OC=>
OVCAR-3 M1zTS2Fxd3C2b4Ppd{BCe3OjeR?= MVmxNOKh|ryP NUSzSHhsOjUEoHi= MWrpcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> M4rXNlI{QDJ4OU[0
OVCAR-3 MmmzSpVv[3Srb36gRZN{[Xl? M1;xO|HjiJNzMNMg{txO MWKyOOKhcA>? M1zreolv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MUSyN|gzPjl4NB?=
OVCAR-3 MULGeY5kfGmxbjDBd5NigQ>? MVOx5qCUOTEEoN88US=> NYfyRYdzOjUEoHi= NV6yRXVPcW6mdXPld{Bnd3KvYYTpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZM> MkfkNlM5OjZ7NkS=
OVCAR-3 MkPDSpVv[3Srb36gRZN{[Xl? M1TESFHjiJNzMNMg{txO NFzyWYszPMLiaB?= MULpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= M370eFI{QDJ4OU[0
MKN45 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn24TWM2ODxyLkCwNUDPxGdxbXy= MmLMNlM4QTN|NEK=
LOVO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;TSllKSzVyPUCuNVIh|rypL33s MonQNlM4QTN|NEK=
A549 NVnl[nM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfhXZJKSzVyPUCuNFQh|rypL33s NVrzVplpOjN5OUOzOFI>
MDA-MB-435 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLoRXc2UUN3MEywMlAxOSEQvHevcYw> MoPNNlM4QTN|NEK=
HepG2 NWXmOI9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHPfXBKSzVyPECuNFAyKM7:Zz;tcC=> MXeyN|c6OzN2Mh?=
HL-60 NYSyPJNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HVOGlEPTB:MD6wNFEh|rypL33s NUjJWodDOjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID